Exogenous IL-4 and IL-13 enhanced the growth of pancreatic cancer cells [25,26], while IL-4-/IL-13-neutralizing antibodies counteracted this effect [18]. This evidence concerns the gene IL4 and familial pancreatic carcinoma.